The global biomarkers market size was valued at USD 101.38 billion in 2025 and is projected to grow from USD 114.44 billion in 2026 to USD 301.65 billion by 2034, registering a CAGR of 12.88% during the forecast period from 2026 to 2034. North America dominated the biomarkers market with a market share of 40.25% in 2025.
Biomarkers are measurable biological indicators that help detect, monitor, or predict diseases, treatment response, and overall health conditions. They can include genes, proteins, hormones, or other molecules found in blood, tissues, or body fluids.
Download a Free Sample To learn more about this report,
Increasing Adoption of Biomarkers in Precision Medicine
Biomarkers are becoming increasingly important in precision medicine by helping identify disease characteristics, stratify patient populations, predict treatment response, and monitor therapeutic outcomes. Their use enables healthcare providers and drug developers to move toward more targeted treatment strategies rather than relying solely on conventional disease classifications.
In February 2026, the U.S. FDA updated its Biomarker Qualification Program submission process, providing more comprehensive instructions for developers seeking regulatory qualification of biomarkers for defined contexts of use.
Growing Integration of Biomarkers With Companion Diagnostics
Biomarker testing is becoming increasingly integrated with companion diagnostics that determine whether patients are appropriate candidates for specific therapies. This is particularly prominent in oncology, where molecular and genomic characteristics can guide treatment selection. Expansion of targeted therapies is consequently encouraging the development of diagnostic assays capable of identifying clinically actionable biomarkers.
In 2025, the U.S. FDA reported that its Center for Devices and Radiological Health authorized 26 oncology in vitro diagnostic devices, including six new companion diagnostic indications and nine expanded companion diagnostic indications.
Increasing Demand for Earlier and More Accurate Disease Detection
Biomarkers can provide measurable biological information that supports diagnosis, disease monitoring, risk assessment, and treatment selection. Their ability to generate objective information from molecular, physiological, imaging, or pathological measurements strengthens their role in modern clinical decision-making.
In September 2025, the U.S. FDA emphasized that biomarkers can support diagnosis, monitoring, prediction, and treatment-response assessment while helping advance the development of medical products.
High Validation Requirements for Clinically Reliable Biomarkers
Biomarker commercialization requires substantial analytical and clinical validation to demonstrate that measurements are reliable and meaningful for a specific intended use. Variability in biological samples, assay methodologies, laboratory procedures, and patient populations can complicate validation. These requirements increase development costs and can extend the time required to translate promising biomarkers from research into routine clinical applications.
In September 2025, the FDA stated that biomarker qualification requires evidence supporting reliable measurement and a clearly defined context of use, with analytical performance of the measurement methods considered throughout the qualification process.
Expansion of Multi-Biomarker and Molecular Profiling Applications
The development of biomarker panels that evaluate multiple biological characteristics simultaneously creates opportunities for more comprehensive disease characterization. Genomic, proteomic, transcriptomic, and other molecular profiling approaches can generate broader datasets for patient stratification and therapeutic development.
In December 2024, the U.S. FDA reported approvals of new next-generation sequencing-based tumor profiling assays with companion diagnostic indications, demonstrating the expanding role of molecular profiling in treatment selection.
Standardization of Biomarker Measurement Across Testing Platforms
Lack of consistent measurement approaches can make it difficult to compare results across clinical studies and healthcare facilities. Establishing reproducible analytical standards while preserving sensitivity and specificity therefore remains a key challenge for biomarker developers and clinical laboratories.
In September 2025, the FDA noted that biomarker qualification is distinct from qualification of the specific test used to measure the biomarker, highlighting the continuing need to establish reliable measurement methods alongside biomarker development.
Safety Segment Dominated the Market with 38.45% Share in 2025
The safety segment dominated the global biomarkers market with a 38.45% share in 2025. Safety biomarkers are widely used during drug development and clinical trials to evaluate potential side effects, monitor treatment safety, and improve patient outcomes. Their critical role in reducing development risks and supporting regulatory approvals continues to strengthen the segment's leading position.
The efficacy and validation segments are also growing steadily. Efficacy biomarkers help assess treatment effectiveness and optimize therapeutic decisions, while validation biomarkers are increasingly adopted to improve diagnostic accuracy and ensure the reliability of biomarker-based tests.
Growing investment in precision medicine and pharmaceutical research is expected to support growth across all biomarker types.
Request Customizationto receive a tailored report.
Diagnostics Segment Dominated the Market with 42.6% Share in 2025
The diagnostics segment dominated the global biomarkers market with a 42.6% share in 2025. Biomarkers are widely used in diagnostic testing to enable early disease detection, improve diagnostic accuracy, and support personalized treatment decisions. Increasing demand for precision diagnostics and non-invasive testing continues to strengthen the segment's leading position.
The drug discovery & development and personalized medicine segments are also witnessing strong growth. Pharmaceutical companies increasingly use biomarkers to improve clinical trial efficiency, identify suitable patient populations, and accelerate drug development, while personalized medicine continues to expand through biomarker-guided treatment strategies.
The others segment also contributes to market growth through applications in disease monitoring, prognosis, and clinical research. Continued advances in molecular diagnostics and genomics are expected to support demand across all application segments.
Cancer Segment Dominated the Market with 39.85% Share in 2025
The cancer segment dominated the global biomarkers market with a 39.85% share in 2025. Biomarkers play a vital role in cancer diagnosis, treatment selection, disease monitoring, and the development of targeted therapies. The increasing global burden of cancer and growing adoption of precision oncology continue to strengthen the segment's leading position.
The cardiovascular diseases, neurological diseases, and immunological diseases segments are also growing steadily. Biomarkers are increasingly used to detect heart conditions at an early stage, monitor neurological disorders, and support the diagnosis and management of immune-related diseases.
The others segment continues to expand as biomarker research advances across infectious diseases, metabolic disorders, and other chronic conditions. Rising healthcare investments, technological advancements, and increasing adoption of personalized medicine are expected to support long-term growth across all disease segments.
Speak to an Analystto discuss market opportunities.
North America biomarkers market accounted for 40.25% of the global market, reaching USD 40.81 billion in 2025, and is projected to grow at a CAGR of 12.84% during the forecast period. Growing use of biomarkers in drug development and personalized treatment is also supporting market growth.
The US market was valued at USD 34.69 billion in 2025, making it the largest contributor in North America. Strong investment in clinical research, increasing adoption of precision medicine, and growing demand for advanced diagnostic technologies continue to drive market growth.
Canada's market reached USD 6.12 billion in 2025. Rising healthcare research funding, expanding biotechnology activities, and increasing use of biomarkers in disease diagnosis continue to support steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe biomarkers market accounted for 29.15% of the global market, reaching USD 29.55 billion in 2025, and is expected to register a CAGR of 14.62% during the forecast period. Growing investment in biomedical research, increasing focus on personalized healthcare, and rising demand for advanced diagnostic solutions are supporting market growth. The region is also benefiting from strong collaborations between research institutions and pharmaceutical companies.
Germany's market accounted for USD 8.57 billion in 2025. A strong life sciences sector, increasing investment in precision diagnostics, and expanding pharmaceutical research continue to support market growth.
The UK market was valued at USD 5.91 billion in 2025. Growing clinical research activities, increasing adoption of biomarker-based diagnostics, and rising investment in biotechnology continue to contribute to market growth.
Asia Pacific biomarkers market accounted for 21.35% of the global market, valued at USD 21.64 billion in 2025, and is projected to register a CAGR of 13.78% during the forecast period. Rising healthcare spending, increasing research in genomics, and expanding pharmaceutical manufacturing are driving market growth across the region. Growing awareness of early disease detection is also creating new opportunities.
Japan's market generated USD 3.90 billion in 2025. Strong investment in medical research, increasing adoption of personalized medicine, and growing demand for advanced diagnostic tools continue to support market growth.
China's market accounted for USD 11.25 billion in 2025, representing the largest share within Asia Pacific. Expanding biotechnology industry, increasing government support for healthcare innovation, and growing pharmaceutical R&D continue to drive market growth.
Middle East & Africa biomarkers market accounted for 3.4% of the global market, totaling USD 3.45 billion in 2025, and is anticipated to grow at a CAGR of 10.86% during the forecast period. Rising investment in healthcare infrastructure, increasing research activities, and growing demand for precision diagnostics are supporting market growth across the region.
The UAE market was valued at USD 1.24 billion in 2025. Increasing investment in healthcare innovation, expanding diagnostic capabilities, and growing focus on precision medicine continue to support market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Cell Counting Market Size, Share, Growth, Analysis, Report, 2034
Capillary Electrophoresis Market Size, Share, Growth, Analysis, 2034
Cancer Microbiome Sequencing Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com